Esperion Therapeutics (ESPR) Stock Price, News & Analysis

Company Overview

Esperion Therapeutics, Inc. is a U.S.-based biopharmaceutical company dedicated to the discovery, development and commercialization of orally administered therapies designed to lower low-density lipoprotein cholesterol (LDL-C) in patients at risk for cardiovascular disease. Originally founded in 1998 and later acquired by Pfizer in 2004, the company was re-established as an independent public entity in 2013 after securing the rights to its proprietary assets. Headquartered in Ann Arbor, Michigan, Esperion combines scientific innovation with a targeted clinical development strategy to address the persistent unmet needs in lipid management.

The company’s lead products, NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid/ezetimibe), represent the first new oral non-statin treatments approved in the United States and European Union for patients with hypercholesterolemia. By inhibiting ATP-citrate lyase, these therapies offer an alternative mechanism to statins and have demonstrated significant LDL-C reductions in both monotherapy and combination settings. Esperion’s pipeline further includes next-generation compounds aimed at improving cardiovascular outcomes and expanding treatment options for high-risk patient populations.

Esperion’s global footprint spans North America and Europe, supported by a commercial infrastructure in the United States and strategic partnerships to facilitate market access abroad. The company engages with regulatory authorities, healthcare providers and patient advocacy groups to advance its mission of reducing cardiovascular risk. Ongoing clinical programs explore additional indications and broader patient cohorts, reflecting Esperion’s commitment to scientific rigor and patient-centric development.

Under the leadership of President and Chief Executive Officer Dr. Martin J. Braddock, Esperion draws on a management team with deep experience in cardiovascular drug development and commercialization. The company’s strategic priorities include strengthening its market presence, accelerating pipeline advancement and forging collaborations to harness emerging scientific insights. Through its focused approach, Esperion aims to establish a new standard of care for patients with elevated cholesterol and cardiovascular disease risk.

Key Stats

• Today's Range: $1.15 to $1.22
• 50-Day Range: $0.73 to $1.22
• 52-Week Range: $0.69 to $3.94
• Volume: 2.32 million shs
• Average Volume: 4.83 million shs
• Market Capitalization: $232.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Moderate Buy

Esperion Therapeutics Stock Analysis - MarketRank™

Esperion Therapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 176th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Esperion Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Esperion Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.29) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Esperion Therapeutics is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Esperion Therapeutics is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.39% of the float of Esperion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Esperion Therapeutics has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Esperion Therapeutics has recently decreased by 8.47%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Esperion Therapeutics does not currently pay a dividend.

Dividend Growth

Esperion Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -2.76

Percentage of Shares Shorted

12.39% of the float of Esperion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Esperion Therapeutics has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Esperion Therapeutics has recently decreased by 8.47%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.71

News Sentiment

Esperion Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Esperion Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 4 people have searched for ESPR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

6 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,706.00 in company stock.

Percentage Held by Insiders

Only 1.70% of the stock of Esperion Therapeutics is held by insiders.

Percentage Held by Institutions

47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ESPR Stock Analysis - Frequently Asked Questions

How have ESPR shares performed this year?

Esperion Therapeutics' stock was trading at $2.20 on January 1st, 2025. Since then, ESPR shares have decreased by 46.8% and is now trading at $1.1710.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) posted its quarterly earnings results on Tuesday, May, 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.03. The biopharmaceutical company earned $65 million during the quarter, compared to analyst estimates of $54.97 million. Esperion Therapeutics had a negative net margin of 59.03% and a negative trailing twelve-month return on equity of 0.91%.
Read the conference call transcript.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Esperion Therapeutics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Marinus Pharmaceuticals (MRNS) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ESPR
• CIK: 1434868
• Web: www.esperion.com
• Phone: (734) 887-3903
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $16.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +497.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.74 million
• Net Margins: -59.03%
• Pretax Margin: -59.03%
• Return on Equity: -0.91%
• Return on Assets: -29.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.18
• Quick Ratio: 0.81

Sales & Book Value

• Annual Sales: $332.31 million
• Price / Sales: 0.70
• Cash Flow: $0.02 per share
• Price / Cash Flow: 48.70
• Book Value: ($1.97) per share
• Price / Book: -0.59

Miscellaneous

• Outstanding Shares: 198,200,000
• Free Float: 194,830,000
• Market Cap: $232.09 million
• Optionable: Optionable
• Beta: 0.70